Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, today announced that it has entered into a definitive agreement to acquire Onspira Therapeutics, a private drug development company similarly focused on therapeutics for rare pulmonary diseases. This acquisition expands Altavant’s pipeline to include OSP-101, a novel inhaled interleukin-1 receptor

Edge Pharma, LLC, a leader in providing allergy immunotherapy solutions, is excited to announce the acquisition of Florida-based Edge Pharmaceuticals, LLC. The two organizations have maintained a symbiotic relationship for the last 7 years in the effort of bringing innovative products and services to the allergy field. This acquisition brings the vast knowledge and expertise

Calibre Scientific is pleased to announce that it has completed the acquisition of the NeXtal Biotechnologies line of structural biology products from Qiagen NV (NYSE: QGEN). NeXtal specializes in the production of unique screens and plates for protein crystallization, an important step in the complex process of structural biology studies and structure-based drug design. NeXtal’s

AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and development, announced today that the Company has signed a binding term sheet to acquire leading oncology research and development company Sapphire Biotech, Inc. (“Sapphire”) as a wholly-owned subsidiary. AXIM and Sapphire intend to enter into Definitive Documents